GlassScriptPhysician profile
Ferdy Santiago
NPI 1104053552
$9,982.78
in general payments reported to CMS, 2019-2025
70 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,812 · 2020: $485 · 2021: $799 · 2022: $1,447 · 2023: $1,051 · 2024: $2,061 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,439.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $745.99 | 2019-2025 | Keytruda, Lynparza, Lenvima |
| E.R. Squibb & Sons, L.L.C. | $665.22 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $610.79 | 2019-2025 | Opdualag, Reblozyl |
| Pfizer INC. | $572.23 | 2019-2025 | |
| Janssen Biotech, INC. | $524.78 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Amgen INC. | $455.19 | 2019-2025 | Kyprolis, Blincyto, Prolia |
| Novartis Pharmaceuticals Corporation | $388.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $367.11 | 2019-2025 | Calquence, Enhertu, Imfinzi |
| Abbvie INC. | $355.97 | 2019-2025 | Venclexta |
| Fennec Pharmaceuticals, INC. | $353.34 | 2024-2025 | Pedmark, Fyarro |
| Daiichi Sankyo INC. | $311.01 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $307.28 | 2020-2025 | Jakafi, Niktimvo, Pemazyre |
| Eisai INC. | $286.67 | 2021-2025 | |
| Astellas Pharma US INC | $262.84 | 2019-2025 | Xospata, Padcev, Xtandi |
| Gilead Sciences, INC. | $207.90 | 2021-2025 | Trodelvy |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdy Santiago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.